Blackstone Inc vs Cronos Group Inc — how do they compare? Blackstone Inc trades at $126.8 (market cap $152.15B), while Cronos Group Inc trades at $2.76 (market cap $1.02B). The key difference: Blackstone Inc is far larger — about 149.2× Cronos Group Inc's market cap, and Blackstone Inc pays a 3.99% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| BX | CRON | |
|---|---|---|
Market Cap | $152.15B | $1.02B |
Sector | Financials | Health |
52-Week High | $188.68 | $3.27 |
52-Week Low | $102.12 | $1.95 |
Dividend Yield | 3.99% | — |
Enterprise Value | — | $203.29M |
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.
Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →